Premium
Effect of ritanserin, a 5‐hydroxytryptamine 2 – receptor antagonist, on platelet function and thrombin generation at the site of plug formation in vivo
Author(s) -
Wagner Brunhilde,
Schneider Barbara,
BlöchlDaum Brigitte,
Speiser Wolfgang,
Brenner Brigitte,
Eichler HansGeorg,
Lechner Klaus,
Kyrle Paul Alexander
Publication year - 1990
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1990.170
Subject(s) - ritanserin , platelet , chemistry , thrombin , pharmacology , thromboxane a2 , medicine , endocrinology , prostaglandin , thromboxane , antagonist , receptor , biochemistry , receptor antagonist
To investigate the role of serotonin in platelet plug formation we studied, in eight healthy volunteers, the effect of ritanserin (a 5‐hydroxytryptamine 2 –receptor antagonist) on the platelet release reaction (represented by β‐thromboglobulin release) platelet prostaglandin metabolism (represented by thromboxane B 2 formation), and thrombin generation (represented by fibrinopeptide A formation) in the microvasculature. After administration of ritanserin lower amounts of thromboxane B 2 were generated in the initial stages of plug formation, suggesting an inhibitory effect on the platelet prostaglandin metabolism. Similar amounts of β‐thromboglobulin were released after the administration of ritanserin compared with placebo, indicating a minor effect of ritanserin on the release reaction. Reduction of thrombin formation by ritanserin in the later stages of hemostasis suggested an inhibitory effect of this substance on the procoagulatory activity of platelets or endothelial cells. This could be attributable to interference with the formation or function of coagulation factor complexes on cell surfaces, or it could be the consequence of a reduction of the platelet activity. Clinical Pharmacology and Therapeutics (1990) 48, 419–423; doi: 10.1038/clpt.1990.170